NYKAA - Fundamental Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Fundamental Rating: 2.9

📊 Financial Overview & Core Metrics

PAT Decline: ₹26.1 Cr → ₹19.0 Cr — ≈27% drop; despite quarter-on-quarter volatility, annualized profit is still underwhelming.

ROCE (9.56%) & ROE (5.16%): Low capital efficiency; doesn’t reflect strong returns on either assets or equity.

EPS (₹0.23): Extremely low — difficult to justify current price using earnings.

Debt-to-Equity (1.01): High gearing, which raises concerns about future interest costs and cash flow strain.

💸 Valuation Snapshot

Metric Value Insight

P/E Ratio 911 Alarmingly high — signals extreme overvaluation

P/B Ratio ~46.2 Massive premium over book value

PEG Ratio 53.0 Suggests price far exceeds earnings growth

Intrinsic Value — Implied to be substantially below market price

🚨 Current valuation seems disconnected from core financial performance — likely driven by narrative and speculative positioning.

💄 Business Model & Strategic Position

Sector: E-commerce with a focus on beauty, wellness, fashion.

Strengths

First-mover advantage in curated beauty e-commerce in India.

High brand recall and customer loyalty.

Growing omnichannel footprint.

Challenges

Rising competition from Amazon, Flipkart, Tata Cliq, etc.

Profitability metrics not keeping pace with revenue scale.

High debt + weakening PAT = risk of margin squeeze.

Institutional Activity

FII ↑ 2.80% — foreign inflow may be chasing momentum

DII ↓ 1.56% — waning domestic conviction

📈 Technicals & Entry Guidance

Current Price: ₹210

DMA 50: ₹205 | DMA 200: ₹189

RSI (50.2): Neutral zone

MACD (2.61): Slight upward bias

Volume: Steady — momentum may persist short-term

🛒 Suggested Entry Zone: ₹170–₹185 Wait for pullback near 200-DMA. Accumulate only if you’re banking on brand growth and long-term sector tailwinds.

🧭 Long-Term Holding Outlook

NYKAA is still a story-driven growth stock, not yet backed by solid financials. If investor conviction remains strong in its lifestyle commerce model and future profitability potential, it may reward patient holders — but at present, the fundamentals and valuation don’t align.

Watch for

Revenue vs profitability convergence

Debt reduction over next 2–3 years

Expansion into private labels and in-house brands for margin uplift

Want to compare with peers like FSN E-Commerce, Mamaearth, or Global fashion retailers next? Could be an eye-opener. Let’s explore if you’re game.

Edit in a page